Catalysts / FBRX
Upcoming FDA decisions and readouts we track for Forte Biosciences, each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for Forte Biosciences (FBRX, listed on Nasdaq). It concerns FB102 (Celiac disease (anti-CD122)).
First on the list: the Phase 2 readout for FB102 (Celiac disease (anti-CD122)), guided by the company to H2 2026.
The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Forte Biosciences FBRX · Nasdaq | FB102 | Celiac disease (anti-CD122) | H2 2026 company guidance |
Phase 2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList